Capital News

Metastatic Colorectal Pipeline Assessment – Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical/Non-Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies

 Breaking News
  • No posts were found

Metastatic Colorectal Pipeline Assessment – Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical/Non-Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies

August 17
21:07 2022
Metastatic Colorectal Pipeline Assessment - Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical/Non-Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 140+ key pharma and biotech companies are working on 140+ pipeline drugs in the Metastatic Colorectal Cancer therapeutics landscape based on different routes of administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

Metastatic Colorectal Cancer Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Colorectal Cancer Market. 

The Metastatic Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

“Metastatic Colorectal Cancer Pipeline” Report covers around 140+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Metastatic Colorectal Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Metastatic Colorectal Cancer Treatment.

  • Metastatic Colorectal Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Colorectal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

Metastatic Colorectal Cancer Therapeutics Landscape

There are approx. 140+ key companies which are developing therapies for Metastatic Colorectal cancer. Currently, G1 Therapeutics has its Metastatic Colorectal cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Metastatic Colorectal Cancer Market include:

G1 Therapeutics, Amgen, Qilu Pharmaceutical, Eisai Co Ltd, Merck Sharp & Dohme, Mirati Therapeutics, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Shanghai Henlius Biotech, Amarin Corporation, Mologen, Sumitomo Dainippon Pharma Oncology, Celltrion, Merck Sharp & Dohme, Jiangsu Hengrui Medicine, Suzhou Zelgen Biopharmaceuticals, Mabpharm Limitied, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical, Isofol Medical, Suzhou Suncadia Biopharmaceuticals Ltd/ Jiangsu Hengrui Medicine, AB Science, Gritstone Bio, Inc, Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Sunshine Guojian Pharmaceutical, Pfizer, Merck KGaA, Jiangsu HengRui Medicine Co., Ltd., ALX Oncology, Immunovative Therapies, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Precision Biologics, Sanofi, GC Pharma, VAXIMM, AstraZeneca, Yooyoung Pharmaceutical, Med Pacto Inc., Exelixis, GlaxoSmithKline, Bristol Myers Squibb, Merck Sharp & Dohme, Bavarian Nordic, Maxinovel Pharmaceuticals, Shanghai Henlius Biotech, Novartis, Zucero Therapeutics, Innovent Biologics, Scandion Oncology, Merck Sharp & Dohme Corp., AbbVie, Beijing Biostar Technologies, Seagen Inc, Merck KGaA, Teclison Ltd, Symphogen A/S, Sichuan Baili Pharmaceutical; SystImmune, Karyopharm Therapeutics, and several others.

Metastatic Colorectal Cancer Therapies covered in the report include:

• Trilaciclib: G1 Therapeutics

• Famitinib: Jiangsu Hengrui Medicine

• CMAB009: Mabpharm Limited

• Trastuzumab Deruxtecan: Daiichi Sankyo

• SCO-101: Scandion Oncology

• BEY 1107: BeyondBio

• Etrumadenant: Arcus Biosciences

And many more

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

Table of Content (ToC)

1. Report Introduction

2. Executive Summary

3. Metastatic Colorectal Cancer Current Treatment Patterns

4. Metastatic Colorectal Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Colorectal Cancer Late Stage Products (Phase-III)

7. Metastatic Colorectal Cancer Mid-Stage Products (Phase-II)

8. Metastatic Colorectal Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Colorectal Cancer Discontinued Products

13. Metastatic Colorectal Cancer Product Profiles

14. Key Companies in the Metastatic Colorectal Cancer Market

15. Key Products in the Metastatic Colorectal Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Metastatic Colorectal Cancer Unmet Needs

18. Metastatic Colorectal Cancer Future Perspectives

19. Metastatic Colorectal Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Report by DelveInsight

Partial Onset Seizures Market
“Partial Onset Seizures Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Partial Onset Seizures Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Partial Onset Seizures therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/